Cite
Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.
MLA
Wu, Zhuo-Xun, et al. “Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.” Cancers, vol. 12, no. 1, Jan. 2020, p. 186. EBSCOhost, https://doi.org/10.3390/cancers12010186.
APA
Wu, Z.-X., Yang, Y., Teng, Q.-X., Wang, J.-Q., Lei, Z.-N., Wang, J.-Q., Lusvarghi, S., Ambudkar, S. V., Yang, D.-H., & Chen, Z.-S. (2020). Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers, 12(1), 186. https://doi.org/10.3390/cancers12010186
Chicago
Wu, Zhuo-Xun, Yuqi Yang, Qiu-Xu Teng, Jing-Quan Wang, Zi-Ning Lei, Jing-Qiu Wang, Sabrina Lusvarghi, Suresh V. Ambudkar, Dong-Hua Yang, and Zhe-Sheng Chen. 2020. “Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.” Cancers 12 (1): 186. doi:10.3390/cancers12010186.